Summit Biolabs
Summit Biolabs, a Colorado-based molecular diagnostics firm, specializes in detecting head and neck cancer recurrence.
Founded
2020Summit Biolabs, a Colorado-based molecular diagnostics firm, specializes in detecting head and neck cancer recurrence.
Summit Biolabs, founded in 2020 and based in Aurora, Colorado, is a molecular diagnostics company specializing in the detection of head and neck cancer recurrence. The company's core mission is to revolutionize molecular testing through pioneering direct-to-PCR technologies, aiming to provide rapid, highly accurate, and robust diagnostic solutions. Summit Biolabs focuses on the healthcare market, particularly in the areas of infectious diseases and oncology, seeking to partner with commercialization entities to deploy their innovative technologies.
Notable figures associated with Summit Biolabs include key researchers and industry experts in molecular diagnostics. The company has gained attention for its transformative approach to molecular testing, leveraging direct-to-PCR techniques that enhance the speed and accuracy of diagnostics. Summit Biolabs' impact is marked by its potential to significantly improve early detection and treatment outcomes for cancer patients, thereby contributing to advancements in personalized medicine and public health.
Companies similar to Summit Biolabs include Prominex, HTG Molecular Diagnostics, Minute Molecular Diagnostics and Molecular Detection.
Summit Biolabs was founded in 2020.
Summit Biolabs' headquarters is located in Aurora, CO, US.
Summit Biolabs' most recent funding round was for $235k (USD) in August 2020.
As of Aug 19, 2020, Summit Biolabs has disclosed funding of $235k (USD). Undisclosed round amounts are excluded.
Summit Biolabs has 9 employees as of Feb 5, 2024.
Molecular Detection
